Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02753855 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetics of Telavancin in Normal and Obese Subjects

A Phase 1 study of Healthy, sponsored by University of Illinois at Chicago.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT02753855 is a Phase 1 study of Healthy that has completed, run by University of Illinois at Chicago. The registered enrollment target is 32 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02753855, a Phase 1 study of Healthy, has completed, sponsored by University of Illinois at Chicago.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to characterize plasma and urinary concentrations of telavancin following intravenous administration of a single dose of telavancin in healthy subjects who are normal weight, overweight, and obese.

Conditions Studied

Interventions

  • DRUG Telavancin

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2016-04
Est. Completion 2016-10
Phase Phase 1

Sponsor

University of Illinois at Chicago

430 total trials

What the Registry Record Tells You About NCT02753855

The ClinicalTrials.gov registry entry for NCT02753855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Telavancin is the first listed.

NCT02753855 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT02753855 about?

NCT02753855 is a clinical study titled "Pharmacokinetics of Telavancin in Normal and Obese Subjects". The purpose of this study is to characterize plasma and urinary concentrations of telavancin following intravenous administration of a single dose of telavancin in healthy subjects who are normal weight, overweight, and obese.

What is the current status of trial NCT02753855?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-04. Estimated completion is 2016-10.

What conditions does trial NCT02753855 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02753855?

The interventions under investigation include: Telavancin (DRUG).

Who is sponsoring clinical trial NCT02753855?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02753855 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.